



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

ML 145

Cat. No.:	HY-107536		
CAS No.:	1164500-72-4		
Molecular Formula:	C ₂₄ H ₂₂ N ₂ O ₅ S ₂		
Molecular Weight:	482.57		
Target:	GPR35; CXCR		
Pathway:	GPCR/G Protein; Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (103.61 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	2.0722 mL	10.3612 mL	20.7224 mL	
		5 mM	0.4144 mL	2.0722 mL	4.1445 mL	
	10 mM	0.2072 mL	1.0361 mL	2.0722 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline					
	Solubility: 5 mg/mL (10.36 mM); Suspended solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC ₅₀ /EC ₅₀ of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC ₅₀ /EC ₅₀ =21.7 μM) ^[1] . ML 145 has no significant activity for GPR35 at either rodent ortholog ^[2] .
IC ₅₀ & Target	IC ₅₀ /EC ₅₀ : 20.1 nM (GPR35), 21.7 μM (GPR55) ^[1]
In Vitro	ML 145 (10 μM) also fully blocks internalization of human FLAG-GPR35-eYFP in response to varying concentrations of Zaprinast, Cromolyn disodium, and Pamoate^[2]. ML 145 is either without effect (mouse) or displays only a small and apparently noncompetitive inhibitory effect (rat) at the rodent orthologs^[2]. ML 145 acts as a competitive antagonist for a number of agonists at human GPR35 and has an IC₅₀ value against EC₈₀ concentrations of various GPR35 agonists in the region of 20 nM^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Heynen-Genel S, et al. Selective GPR35 Antagonists - Probes 1 & 2. National Center for Biotechnology Information (US); 2010-2010 Feb 28.
- [2]. Laura Jenkins, et al. Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J Pharmacol Exp Ther. 2012 Dec;343(3):683-95.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA